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Abstract: The Objective of this paper is to test the consequences of changes in health status of future 
cohorts of French elderly on healthcare expenditures. We value the precise effect of epidemiological 
and life expectancy changes on health expenditures for 2025 by using a markovian microsimulation 
model for a representative database of the contemporary cohorts in France. The originality of these 
simulations holds in the use of an aggregate indicator of morbidity-mortality, capturing a vital risk 
and making possible to adapt the quantification of the life expectancies by taking into account of a 
life without incapacity and/or of the presence of severe pathologies. We forecast a reliable range for 
future national health spending, under different epidemiological scenarios of morbidity: benchmark 
case (BM), healthy aging (HA), healthy aging and medical progress (AM). We obtain an evaluation of 
the annual growth rates in health expenditure accounted for solely by aging: +1.18%; +0.95%; +1.38% 
according to the scenarios BM; HA; AM. In short, the effective decreases in morbidity rates are not 
sufficient enough to compensate the massive arrival of baby-boomers at elderly age in France for the 
period 2010- 2025. 
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Introduction 
 
The factors explaining the increase in health expenditure are generally divided into two types: 
demographic factors (aging of the population, lengthening of the lifespan and epidemiologic 
changes) (Bebbington et Shapiro, 2005) and non-demographic factors (income elasticity, price 
elasticity, technology and medical practices) (see Dormont, Grignon et al., 2006 for  a comprehensive 
decomposition of these effects for France, see also EC-EconomicPolicyCommittee, 2005; EC-
EconomicPolicyCommittee, 2006; OECD, 2006). Macroeconomic projections of health expenditures 
insist on sensitivity of their results to epidemiologic evolutions (Oliveira Martins et De la 
Maisonneuve 2006), but can take them into account only by making ad hoc assumptions on these 
evolutions and by sacrificing microeconomic dimension. In the context of population aging, the stake 
is to determine the future prevalence (“stocks”) of chronic diseases (Verbrugge et Jette, 1994). If one 
wants to be rigorous, simulation of epidemiologic changes must be realized through assumptions on 
incidence rates (“flows”). In this paper we make it possible to carry out prevalence projections from a 
set of formulated on incidence to get the precise effect of epidemiological and life expectancy 
changes on health expenditures for 2025 by using a microsimulation model. Such simulations are 
impossible using a “macro” method. Macrosimulation relies on modifying the weights of the sick and 
non-sick populations via ad hoc assumptions about future prevalence rates, which inevitably decide 
the aggregate consequences of the scenarios (VanImhoff et Post, 1997). 
Internationally, some efforts were carried out, operating this new applied modeling method in the 
field of health (Marquis et Long, 1997; Zabinski, Selden et al., 1999; Gruber, 2000), the technique 
itself borrowed from tax analysis (Citro et Hanushek, 1991; Mot, 1992). But few models were 
interested in a macroeconomic diagnosis of health expenditure and its evolution at a far horizon 
(2025). The work of Rand Corporation (which is similar to our model) concerns the particular 
population of 65-plus people eligible to the Medicare program in the United States. Characteristics of 
the US population -particularly that of Medicare- require taking into account specific scenarios from 
the French case in particular because of the bad health of the new American cohorts (e.g. the obesity 
and diabetes epidemic) (Goldman, Shang et al., 2005). Another example is the paper of Dormont, 
Grignon et al., 2006 which breaks up perfectly the effects “morbidity shift” and “seeking care 
intensity”, but on retrospective data not yet integrating the epidemiologic change assumptions of 
width advanced for example by Michel et Robine, 2004 for the future generations of sixty-plus.  
The originality of these simulations holds in the use of an aggregate indicator of morbidity-mortality, 
capturing a vital risk and making possible to adapt the quantification of the life expectancies by 
taking into account of a life without incapacity and/or of the presence of severe pathologies. Breyer 
et Felder, 2006 showed that models integrating a better predictor of healthcare needs than 
chronological age (they used a “time to death index”) gives more precise estimates while measuring 
the effect of aging on health expenditures. As well, Shang et Goldman, 2008 showed that life 
expectancy has a bigger predictive power than chronological age but diminishes while introducing 
health indicator. They also have shown that this drives to a lower projection of future health 
expenditures. In the context of healthy aging, these findings suggests that introducing health status 
and life expectancy into the model of spending may lead to a lower estimate than when using 
chronological age only. Then using this index drives to get a more precise prediction model. 
 Methods 
Databases 
Two databases were used to perform the simulations. Participant data from the administrative set of 
data the Public Insured Permanent Sample (EPAS) and the Health and Social Protection Survey 
(ESPS2000) were united to form a single database. Social security numbers were used to match 
respondents across datasets. The EPAS exhaustively details all health reimbursed expenditure made 
by members of the National Insurance. A major advantage of the EPAS is that it contains exact 
expenditure data, which circumvents the inconsistencies generated in self-report questionnaires. A 
limitation is that ambulatory (i.e. non hospital) expenditure data are complete, whereas the hospital 
data could miss –because they are not gathered individually, but as a “collective spending” (public 
good). Consequently, only ambulatory care expenditure data were used in this study. In Metropolitan 
France, ESPS data has been collected via self-administered questionnaires every two years since 
1988, by the IRDES/CREDES. It comprises a nationally representative sample of 22,000 National 
Insurance Scheme members from 8,000 households. The major advantage of this database within the 
current study framework is that it contains a wealth of additional information complementary to the 
EPAS, including individual and household demographic characteristics, epidemiologic data including 
several synthetic indicators of health conditions and socio-economic data. United, the ESPS and EPAS 
provide the most accurate, comprehensive, and representative health expenditure and social health 
data on the French population. The combined database comprised 5,944 observations, weighted to 
represent the total metropolitan population. 
Morbidity- Mortality Index: Taking into account “Time to Death” 
The Morbidity-Mortality Index is built from two health-related indexes found in the ESPS2000 data 
base: a vital risk and a disability index, both rated by medical doctors on the basis of the individuals’ 
interview (by telephone and by self-questionnaire, reporting all past and present diseases of agents). 
Vital risk corresponds to the death likelihood level and is rated on a 6-point Likert scale (Likert, 1932) 
from “no essential risk” to “a definite poor prognosis” and defined as an 80% probability of death 
within five years. The disability index captures the  disability level induced by chronic conditions and 
is rated on an 8-point Likert scale from “no impairment” to “permanently bed-ridden” (Perronnin, 
Rochaix et al., 2006). We decided to also use this latter index in order to increase the significance of 
our final indicator in the econometric model (people with disability are great consumer of health care 
even when vital risk is low). From both variables, we created an aggregate indicator (see appendix A). 
This morbidity/mortality index gives aggregate information of the diseases and the life expectancy of 
the individual at the time of the survey. It makes possible to predict the future expenditure by 
getting a foreseeable individual epidemiologic dynamics on this aggregate indicator with no need for 
a projection of the whole diseases range. 
 
Aging process: Markovian methods 
First future individual’s health status is forecasted using a microsimualtion model according to the 
following: From time t, an individual is either in good health, or bad health, or dead; at the next time, 
in t+1 (one period lasts 5 years), the same person’s health is determined by a transition rates matrix 
according to his last health status. The transition rates matrixes contain probabilities of transition 
from a given health status towards another. We consider a matrix by age group (5 year age brackets) 
and by gender  
 
,  , 	… / … where , is the health status of person  at time  and / the 
transition probability between state  and . 
 
,  ,  , 	… / … where  is the cost vector of representative individual 
 given by the two-part econometric model. 
Transition rates are estimated from cross sectional data in 2004. The transitions are computed for 
each age group and each gender. They are then modified by shifting the transition probabilities to 
obtain the scenarios. The model does not take into account any assumption of immigration; the 
population studied for 2025 is exactly the same one as in 2000, less dead people. 
In the “Benchmark” Scenario (BM) the risk of falling sick is held constant. The matrixes of the BM 
case refer to the current morbidity and mortality rates. The former are directly induced from a cross-
sectional use of the database and the latter are given by the mortality tables adjusted by age and the 
year of birth. Thus, after simulations of health status and consecutive expenditures, we will obtain 
the amount of the expenditure rise related to the demographic effects only. Differences in 
expenditures come only from changes in the population pyramid (the “grandpa boom”, with larger 
population sizes for the older age brackets). 
In the “Healthy Aging” Scenario (HA) the incidence is modified: morbidity rates decrease, “relative” 
life expectancy remains constant. To obtain the matrixes of this scenario the probabilities “from good 
health to good health” are shifted two age brackets for men and one age bracket for women. So the 
share of healthy days and unhealthy lifespan is changed in the total lifespan. It is a scenario of 
“Healthy Aging” in the sense that days in good health will increase in the total life-time of future 
aged individuals without direct changes of lifespan (i.e. without direct change in death rates). But 
there is an indirect effect of increase in lifespan while only the probabilities of becoming sick are 
changed: less people die because healthy people death rates are lower than for sick people. This 
translated the theory of Robine, 2007 on aging and the rectangularization of the survival curve. 
In the “Advance in Medicine” Scenario (AM) technology is assumed to reduce the death rates of 
unhealthy people (by the transformation of fatal diseases into chronic diseases), and to keep people 
healthy and alive for longer. The matrixes of the “Advance in Medicine” scenario are thus the result 
of a shift of all probabilities (two age brackets for men and one age bracket for women, as before). 
In this paper, the effects of medical progress are simulated in terms of demographic consequences 
only. We did not include a scenario of changing cost. The issue of the evolution of the price index for 
healthcare is a complex one, particularly given the myriad ways in which medical progress may occur. 
Broadly speaking, productivity gains due to technology generally reduce the relative price of 
healthcare, while costs associated with the development and implementation of new technology 
generally raise it. In the current study, we have chosen to make the conservative assumption that 
the price index of healthcare remains constant in real terms - it evolves at the same rate as the GDP 
price index. The demographic effects of (healthy) aging are modelled “all other things being equal”. 
 
Acute Care Expenditures Forecasting Model 
We used a micro-econometric model to forecast health expenditures for each individual. As noticed 
earlier the administrative data exhaustively recorded ambulatory expenditures only. These 
expenditures include spending occurring outside hospital such as practitioner visits and cares, 
biological tests, pharmaceutical products, medical equipments, optical care and products (glasses), 
prosthesis and orthotics. 
A sequential “two-part” econometric model (Manning, Morris et al., 1981) was chosen over three 
alternatives commonly used to model health care expenditures (see  Jones, 2000; Deb et Trivedi, 
2006 for a review of these models). In the French system, the family physician is the gatekeeper to 
whom a citizen must present to obtain health care. The physician then decides how much the system 
will spend on the patient by allocating health care resources including drug prescriptions and by 
orienting them towards relevant health services. This sequential two-part process is best captured by 
the two-part model. The first part of the model, the probability to seek care, was estimated through 
a Logit model. The log-transformed level of expenditure (which addressed the skew problem) was 
then estimated with an OLS model using one smearing factor to correct for heteroskedasticity (see 
Buntin et Zaslavsky, 2004 for a detailed explanation about the way to choose a particular technique 
to forecast health expenditures). 
As shown in table 1, health status was the strongest predictor of care seeking behavior, followed by 
age, gender, and private health insurance. The ill, elderly, women, and privately insured were the 
most likely to engage with the health system. Similar trends were observed for expenditure. 
 
Results 
Projected demographic structures 
The population pyramids in Figure 1 illustrate the effects of the simulated epidemiologic changes on 
the demographic structure of the population. These pyramids are first characterized by their tops, 
that is to say, by the demographic structure of the elderly populations. The pyramid relating to 
scenario BM shows the trends prolongation of current population (aged baby boomer). The median 
part of pyramid ESPS2000 is found quasi mechanically at the top of pyramid BM. A generational 
imbalance is apparent, with decreasing number of young compared to the 60-plus. Moreover, the 
joint effect of baby-boom and lifespan lengthening results in a sizeable enlargement of the 90-plus 
population. Under the scenario of “healthy aging”, 60 plus people are more numerous than in BM. 
This is due to the second order effect; the fall of morbidity involves a fall of mortality (Cf scenarios 
description). 
The “advance in medicine” scenario results in an even stronger difference from the BM, with a 
consequent widening of the pyramid top. It is the expression of the first order effect of mortality fall 
among the oldest age groups. This extreme case shows the risk of a total upheaval of the relationship 
between the potential numbers of workers and retirees (EC-EconomicPolicyCommittee, 2001). 
Table 2 shows an increase of the 60-plus, from 28% to at least 43% (among the 25-plus) between 
2000 and 2025 in the most favorable case. When compared to the tendency prolongation scenario 
(BM), the healthy aging scenario will potentially reduce the share of unhealthy people among the 
older (60 plus) population by 5.87 percent. Under the AM scenario, the numbers of unhealthy and 
healthy people are respectively 30% and 10% superior to the BM scenario. 
Analyses of projected health expenditure 
The econometric model integrates age under three dimensions, which confers its particular empirical 
form on the expenditure profile, initially increasing then decreasing as survivors move into the 
highest age groups (Figure 2). This translates the effect of catastrophic expenditure (proximity to 
death), which is high for old persons but which tends, however, to be relatively less important when 
people reach an age beyond 90 years (with probably a weaker technico-medical investment to keep 
these people alive, see Shoven, 2004 for an equivalent effect). Thus, population aging consequences 
on health expenditure depend on a subtle balance between population repartition across age groups 
and the epidemiologic evolutions. Note that the chronological variable of age thus remains 
determinant of expenditure level; perhaps capturing the marked increase in health prevention 
behaviors practiced by aged-populations, whatever their health status.  
At the turn of the millennium in France, expenditure distribution across age groups was rather 
uniform. However, the three projections in this study estimate a net imbalance in 2025. Longer 
lifespan will see the volume of expenditure accounted for by the 60-plus population increase 
considerably. This rise is directly related to the increasing number of people in these older age 
groups. Comparisons of expenditure between the various scenarios of aging suggest that `healthy 
aging' scenario results in a light profit (5% on average) compared to the BM. The graphs of scenarios 
BM and HA are very close; the variation is really visible only for the higher age groups (after 60 
years). Taken together, the results suggest that it is the number of elderly persons which determine 
the amount of expenditure, rather than their distribution between healthy and unhealthy states. The 
effect of an increase in life expectancy (scenario AM) on expenditure is more strongly inflationary. A 
longer living population means that both the number of healthy people and unhealthy people 
increase. The groups aged 75-plus will place the greatest pressure on health expenditure, since this is 
where the population is projected to experience the greatest growth (cf population pyramid). 
 
Table 3 highlights the impact of the projected aged population increase, in terms of expenditure 
distribution between healthy and unhealthy persons, and the share devoted to the 60 plus 
population. On the whole, the pure effect of the aging French population is likely to generate an 
increase in expenditure of 34% (comparison 2000/BM for 25 plus people). Under scenario BM, 
population aging contributes to a rise of 1.18% to the annual expenditure growth rate. Under the 
healthy aging scenario, a rise of 26.7% or 0.95% annually is projected. 
Discussion 
The model is able to forecast a reliable range for future national health spending, under different 
epidemiological scenarios for disability (benchmark case, healthy aging, healthy aging and medical 
progress). These scenarios are mainly based on the theories of aging of Robine et Michel, 2004 and 
allow to quantify precisely the future effect on health expenditure of various epidemiologic 
alternatives. This work thus rests on a double approach, both epidemiologic and economic (a 
“disease oriented model” according to Jacobzone, 1999). The first scenario, BM, forecasts health 
expenditure arising in a future in which actual health trends continue 25 years into the future 
(Bebbington et Shapiro, 2005). The second, HA, simulates a scenario of ‘healthy aging’ or reduced 
morbidity, brought about by a reduction of the risk to become chronically ill, in which the 
probabilities of falling sick are simulated to be smaller than those currently observed. This scenario 
actually leads to a “natural” lifespan lengthening: the population is less likely to have chronic 
condition so the average lifespan is increased. In the third one, called AM “advance in medicine”, we 
add an increase in life expectancy to the healthy aging. 
Simulations results show that “healthy aging” is not sufficient to attenuate the flow of expenditures 
created by population aging. The principal element of the explanation is that, as showed by results, 
health consumption is strongly increasing with age, whether people are unhealthy or otherwise. If 
mortality rates decrease due to medical innovations (AM), the number of chronically ill survivors 
increases as does the number of healthy people aged 60-plus. Healthy aging consequently 
counterbalances even less the expenses flow generated by population aging. Results give a precise 
evaluation of the annual growth rates in health expenditure accounted for solely by aging: +1.18%; 
+0.95%; +1.38% according to the scenarios BM; HA; AM, which is a little higher than the evaluation 
given by a study on French retrospective data: +0.8% Azizi et Pereira, 2005. However they studied 
the period 1970-2002 and insist on the fact that this rate will increase in the future. One can fear a 
situation more alarming for expenditure in long term care (nursing homes, supporting disabled 
elderly) (Norton, 2000), because the figures presented here relate only to ambulatory expenditures. 
Indeed, expenditures on care for the elderly includes spending in domestic care (either not recorded 
or badly taken into account by the “health accounts”) and in long hospital stays. One could thus 
expect rises in long term care expenditure proportionally greater than the ambulatory sector. By 
simulating ambulatory expenditure only, we undoubtedly minimize the impact of aging, even by 
considering only the growth rates. 
In spite of an individual risk reduced to be sick, the growth of elderly populations under the effect of 
the demographic trends prevailing in France, lead to an important increase in the number of sick 
people - purely mechanical effect. Moreover individuals in good health are more numerous and, in 
spite of their good health status, their consumption is non zero and also increases with age. The 
solutions for France to deal with its aging concern is not necessarily to decrease the care given to the 
chronically ill, but maybe to make the healthy population think differently about the way they 
consume healthcare (consumerism). However, the added effect of this consumerism on healthy 
aging is not known. One could imagine that it is an investment in human health capital and would 
lead to a “healthier” population, maybe less expensive to take in charge when experiencing tangible 
bad health and time-to-death period.  
  
Tableau 1: Probability to seek care and level of expenditure (two part model estimation on full sample) 
 Two Part Model  
 Pr(Seek Care) Log (expenditure) 
Intercept   1. 82***   6. 44*** 
Good Health - 0. 24*** - 0. 74*** 
Age - 0. 20*** - 1. 26 10
-2
** 
Age²   0. 003**   7. 85 10
-4
*** 
Age
3
 - 10
-5
* - 5. 50 10
-6
*** 
Male - 0. 18*** - 0. 32*** 
No Private  
Health Insurance 
- 0. 12* - 0. 07* 
*Significant at 10%; **significant at 5%; ***significant at 1%. 
 
Tableau 2: 25+ population distribution according to scenarios 
 ESPS2000 BM HA AM 
Unhealthy people 29. 35 % 37. 26 % 30. 84 % 34. 78 % 
60+ among the 25+ 28. 10 % 42. 94 % 45. 26 % 48. 10 % 
Unhealthy people among the 60+ 56. 49 % 57. 73 % 47. 81 % 53. 68  % 
TOTAL 25+ Population in Million 41. 45 46. 19 46. 73 49. 55 
TOTAL 60+ Population in Million 11. 64 19. 84 20. 37 23. 02 
 
Tableau 3: Health expenditures in 2025 compare to 2000 
 ESPS2000 BM HA AM 
25+ acute care spending 47.0 Billion Euros +33.94  % +26.68 % +40.90 % 
Unhealthy 25+ spending 25.5 Billion Euros +53.51 % +20.50 % +46.71 % 
60+ spendings 24.5 Billion Euros +63.62 % +53.42 % +79.59% 
Unhealthy 60+ spendings 18.0 Billion Euros +67.20 % +30.28 % +65.82% 
 
  
  
 
Figure 2: Predicted effect, by the econometric model, of age on health expenditure after taking health status into 
account 
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Figure 1: Age pyramids according to scenarios 
Figure 3: Health care spending according to age groups and scenarios 
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Appendix A: morbidity-mortality index 
 
Disability 
Vital 
Risk 
0: No Vital 
Risk 
1: Very 
Low  
2: Low 3: Possible 
Vital Risk 
4: Poor 
Prognosis 
5: Very Poor 
Prognosis 
Total 
0 : No Disability  16,24% 1,71% 0,74% 0,09% 0,00% 0,00% 18,77% 
1 : Minimal Disability  8,66% 3,31 % 1,84% 0,42% 0,00% 0,00% 14,23% 
2 : Few Disability  7,87% 5,25% 13,77% 1,88% 0,00% 0,00% 28,77% 
3 : Disability, but Normal 
Living 
 
2,30% 2,16% 13,36% 5,16% 0,31% 0,00% 23,29% 
4: Have to Decrease 
Professional and 
Household Activities 
 
0,31% 0,44% 2,99% 5,31% 2,36% 0,14% 11,54% 
5 : Low Autonomy  0,04% 0,04% 0,17% 0,78% 1,48% 0,32% 2,83% 
6 : No Household 
Autonomy 
 
0,00% 0,03% 0,00% 0,09% 0,16% 0,21% 0,49% 
7: Full time Confinement 
to Bed 
 
0,00% 0,00% 0,00% 0,02% 0,06% 0,00% 0,08% 
Total  35,42% 12,94% 32,86% 13,75% 4,37% 0,67% 100% 
 
The “healthy” status is defined by the lighter part of the table above. 
 
 
